systemic%20lupus%20erythematosus%20(pediatric)
SYSTEMIC LUPUS ERYTHEMATOSUS (PEDIATRIC)
Systemic lupus erythematosus (SLE) is a chronic, multisystem, inflammatory, autoimmune disorder characterized by formation of autoantibodies directed against self-antigens and immune-complex formation.
Clinical presentation varies in different patients and the disease activity varies over time in a single patient. Childhood-onset SLE has a greater disease severity and earlier disease damage than in adults with SLE.

Systemic%20lupus%20erythematosus%20(pediatric) Treatment

Principles of Therapy

Patients require individualized therapy depending on disease manifestations, activity and severity

Goals of Therapy

  • Control disease manifestations, ie aim for remission or low disease activity and flare prevention  
    • Complete remission is no clinical activity (SLEDAI = 0) without use of corticosteroids and immunosuppressants    
    • Low disease activity is SLEDAI ≤4, PGA ≤1, corticosteroid use of ≤7.5 mg/day of Prednisone, and well-tolerated immunosuppressants in stable doses
  • Allow the child to have a good quality of life without major exacerbations
  • Prevent serious organ damage that adversely affects function or life span
  • Prevent adverse effects of the drugs used

Pharmacotherapy

Corticosteroids

Oral Corticosteroids

  • Patients with mild SLE do not normally require use of systemic corticosteroids but there are patients whose quality of life is not improved if not given low-dose corticosteroids
    • Patients on remission or with low disease activity should be maintained with the lowest possible glucocorticoid dose
  • Decrease inflammation by suppressing the immune system  
    • Decrease lymphocyte volume and activity, PMN migration, capillary permeability
  • Used as initial therapy for severe discoid lupus erythematosus or lupus vasculitis
  • Low-dose corticosteroids may be added to Hydroxychloroquine for fatigue and fever
  • High-dose corticosteroids are necessary for refractory manifestations of SLE and for severe organ systems’ manifestations especially CNS, renal and hematologic manifestations
    • Show improved survival in patients with severe forms of SLE nephritis
    • May also be useful in severe, life-threatening thrombocytopenia and hemolytic anemia
    • May also be useful in pleuritis or pericarditis
  • Consider adding a steroid-sparing agent if a glucocorticoid dose of >0.35 mg/kg/day is required for >3 months
  • Corticosteroid use should be <7.5 mg/day (Prednisone equivalent) during chronic maintenance therapy and tapered (and if possible withdrawn) as soon as desired response is observed (control of inflammatory manifestations) to avoid toxicity
    • Tapering or withdrawing of corticosteroids may be hastened with the prompt initiation of immunosuppressants  
    • High doses over periods of >2-3 weeks suppress adrenal function
Topical Corticosteroids
  • Helpful for discoid lesions especially on the scalp
  • Use a less potent steroid on the face because it is more prone to atrophy
Parenteral Corticosteroids
  • IV pulse dosing of Methylprednisolone gives immediate therapeutic effect and allows the initiation of oral corticosteroids at a lower dose  
  • Pulse therapy with IV corticosteroids with or without immunosuppressive therapy can be given to patients with severe organ or life-threatening manifestations

Disease-Modifying Anti-Rheumatic Drug (DMARD)

Hydroxychloroquine
  • Inhibits chemotaxis of eosinophils and locomotion of neutrophils and impairs complement-dependent antigen-antibody reactions
  • Recommended for all SLE patients without contraindications 
  • Used for skin and joint manifestations
    • Useful for patients with skin disease that is unresponsive to topical corticosteroids and in patients with arthritis that does not respond to NSAID
  • Recommended as background treatment for class III/IV SLE patients with nephritis
    • Patients with continuing treatment with Hydroxychloroquine showed less renal damage as compared to those on placebo
  • Also used for preventing flares and other constitutional symptoms

Immunomodulatory Agents

Choice of immunomodulatory agent will depend on nature and severity of disease manifestation

  • These agents act as immunosuppressive, cytotoxic and anti-inflammatory agents
  • Consider the addition of immunosuppressants in patients unresponsive to Hydroxychloroquine therapy (with or without corticosteroids) or unable to decrease corticosteroid doses below that acceptable for chronic use
  • Can be included in the initial treatment of organ- or life-threatening SLE wherein an initial course of high-intensity immunosuppressive therapy is given followed by a longer course of less intensive treatment to consolidate patient’s response and prevent relapses
    • In the treatment of severe CNS and severe glomerulonephritis, thrombocytopenia and hemolytic anemia, high dose glucocorticoids and immunosuppressants are used
    • Concomitant use with corticosteroids allows lower doses of immunosuppressants
Azathioprine
  • Antagonizes purine metabolism and inhibits synthesis of DNA, RNA and proteins 
  • May decrease proliferation of immune cells resulting in lower autoimmune activity
  • A steroid-sparing agent in non-renal SLE and prevents flares
  • May be used as an immunosuppressant for SLE nephritis and hematologic and dermatologic manifestations

Methotrexate

  • Blocks purine synthesis and increases anti-inflammatory adenosine concentration at sites of inflammation
  • Used for mild to moderate non-renal SLE and prevents flares
  • May be used as the initial immunosuppressant for severe arthritis

Mycophenolic acid

  • A reversible inhibitor of inosine monophosphate dehydrogenase which is the rate-limiting step in de novo purine synthesis  
  • Effective for both renal and non-renal lupus and certain neuropsychiatric diseases  
    • Used for moderate to severe non-renal SLE and prevents flares   
    • Recommended as induction and maintenance therapy for patients with lupus nephritis and has shown better results (less adverse effects and infections) as compared to IV Cyclophosphamide  

Calcineurin Inhibitors

  • Eg Cyclosporine A, Tacrolimus
  • Can be considered in the treatment of class V lupus nephritis or select cases of refractory lupus nephritis
Cyclophosphamide
  •  As an alkylating agent, may involve cross-linking of DNA which may interfere with growth of normal and neoplastic cells
  • Used as the initial immunosuppressant for SLE nephritis
    • Concomitant use with Prednisone is the standard treatment for lupus nephritis as it helps preserve renal function
  • Given to children with moderate or severe SLE who cannot be maintained on a dose of Prednisone at <0.5 mg/kg/day and other steroid-sparing agents  
  • Useful for severe organ- or life-threatening SLE (eg severe CNS, cardiopulmonary or renal involvement) and as rescue therapy for non-major organ manifestations unresponsive to other immunosuppressants  
  • Prevents lupus flares
Intravenous Immunoglobulin (IVIg)
  • Neutralizes circulating myelin antibodies through anti-idiotypic antibodies
    • Down-regulates proinflammatory cytokines, including interferon-gamma
    • Blocks receptors on macrophages, suppresses inducer T and B cells and augments suppressor T cells
    • Blocks complement cascade, promotes remyelination and may increase colony stimulating factor IgG
  • Used in serious SLE flares and refractory severe lupus
  • May be considered in the acute phase of lupus thrombocytopenia if there is an inadequate response to high-dose corticosteroids or to prevent infectious complications from corticosteroid therapy

Biologic Therapies 

Belimumab

  • The first US FDA-approved biologic therapy for the treatment of SLE
  • A human monoclonal antibody that binds to soluble B-lymphocyte stimulator (BLyS/BAFF) to reduce disease activity 
  • Used for patients with active, autoantibody-positive SLE with a high degree of disease activity (eg positive anti-dsDNA and low complement) despite standard therapy (Hydroxychloroquine and corticosteroid combinations with or without immunosuppressants)  
  • Considered as an add-on therapy to extrarenal disease that is persistently active or flaring, or to patients with frequent relapses and/or residual disease activity preventing corticosteroid tapering
  • Studies have shown that patients on Belimumab therapy experienced reduced risk of severe flares, improved health-related quality of life and reduced steroid use as compared to those on placebo
  • Not recommended for patients with severe active lupus nephritis or severe active CNS lupus

Rituximab

  • A biologic, it is a chimeric monoclonal antibody to CD20 antigen which regulates cell cycle initiation  
  • Used as rescue therapy for SLE patients with organ-threatening disease refractory or with intolerance or contraindications to standard immunosuppressive therapy
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Inhibit inflammatory reactions and pain by decreasing prostaglandin synthesis 
  • These drugs provide symptomatic relief of fever, arthritis and mild serositis, ie controls symptoms in mild non-renal lupus 
  • SLE patients have a high incidence of NSAID-induced hepatotoxicity

Specific Manifestations and Comorbidities of SLE

Specific Manifestations of SLE

Lupus Nephritis

  • Patients suspected to have lupus nephritis should immediately undergo renal biopsy to confirm diagnosis, evaluate severity, determine prognosis and therapy
  • Indications for renal biopsy in SLE patients:
    • Unexplained increase in serum creatinine in the absence of alternative causes (eg sepsis, hypovolemia, medications)
    • Confirmed proteinuria of ≥1 g/24 hr or reproducible proteinuria of ≥0.5 g/24 hr plus glomerular hematuria and/or cellular casts  
  • For induction of treatment, Mycophenolate or low-dose IV Cyclophosphamide are recommended  
    • Consider giving the same regimens or use high-dose IV Cyclophosphamide in those at high risk of renal failure or those with adverse prognostic factors   
  • Initial combination of treatment regimens with 3 consecutive pulses of IV Methylprednisolone then followed by oral Prednisone helps increase efficacy and decrease cumulative corticosteroid dose  
  • Azathioprine or Mycophenolate should be used for maintenance treatment  
  • Patients with severe nephrotic syndrome or incomplete renal response without a decreased GFR, uncontrolled hypertension and/or kidney biopsy with a high chronicity index can be given Mycophenolate combined with low-dose calcineurin inhibitor  
  • Rituximab can be given to refractory disease  
  • Monitoring of lupus nephritis includes a BP check and lab tests such as urinalysis, protein/creatinine ratio, serum creatinine, C3/C4 and anti-DNA levels

Neuropsychiatric SLE (NPSLE)

  • Monitor SLE patients for neurological and/or psychiatric manifestations as in non-NPSLE patients
  • Usually appears within 1 year from the time of diagnosis; may also appear before or at the time of diagnosis 
  • Diagnostic work-up may include the following: 
    • Lumbar puncture  
    • Nerve conduction studies (NCS)  
    • Neuropsychological assessment of cognitive function  
    • Cerebrospinal fluid analysis  
    • Electroencephalography (EEG)  
    • Neuroimaging: T1/T2 MRI, diffusion-weighted imaging, gadolinium-enhanced T1 sequences  
  • Manifestations indicating an inflammatory process are treated with corticosteroids and/or immunosuppressants while atherothrombotic or antiphospholipid-related manifestations are treated with antiplatelets/anticoagulants  
  • Patients found to have NPSLE should be referred to a team of psychiatrists, psychologists, neurologist and rheumatologist

Skin Disease

  • Initial management includes use of topical agents (corticosteroids, calcineurin inhibitors), antimalarials (Hydroxychloroquine, Quinacrine) with or without systemic corticosteroids  
  • Consider adding Methotrexate, Mycophenolate, Dapsone or retinoids to unresponsive patients or those who need high-dose corticosteroids  

Hematological Disease

  • Lupus thrombocytopenia can be acutely treated with moderate to high doses of corticosteroids (including IV pulse dosing of Methylprednisolone) in combination with immunosuppressants and/or IVIg  
  • Azathioprine, Mycophenolate or Cyclosporine can be used for maintenance therapy  
  • Refractory patients can be given Rituximab or Cyclophosphamide

Comorbidities of SLE

Cardiovascular Disease

  • Regularly evaluate SLE patients for traditional and disease-related risk factors for cardiovascular disease, eg persistently active disease, increased disease duration, chronic use of corticosteroids, persistent proteinuria and/or GFR <60 mL/min and medium/high titers of antiphospholipid  
  • SLE patients may be given low-dose Aspirin and/or lipid-lowering agents based on their individual cardiovascular risk profile  

Infectious Diseases

  • Evaluate SLE patients for general and disease-related risk factors for infection, eg frailty, renal disease, DM, use of corticosteroid and immunosuppressive therapy  
  • Early diagnosis and treatment of infection or sepsis and general preventive measures, eg immunizations, are recommended

Antiphospholipid Syndrome

  • Antiplatelet agents as primary prophylaxis may be given to SLE patients with a high-risk antiphospholipid profile, especially if with other atherosclerotic or thrombophilic factors, after considering potential for bleeding  
  • Management for secondary prevention (thrombosis, pregnancy loss/complication) should be the same as for primary antiphospholipid syndrome  

Malignancies    

  • May include non-Hodgkin's lymphoma, thyroid, lung, cervical and vulval cancer  
  • Perform cancer screening and manage according to established guidelines for the specific condition  

Macrophage Activation Syndrome (MAS)

  • A rare but severe and potentially life-threatening complication of cSLE  
  • In clinically unstable patients in whom MAS is suspected, treatment should be initiated immediately if a bone marrow aspirate cannot be performed
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
02 Apr 2019
Using preventive zinc and micronutrient powder supplementation does not appear to improve growth in children, a recent study has found.
Audrey Abella, 14 Oct 2020
Findings from the phase IIa T1GER study revealed the therapeutic potential of the monoclonal antibody golimumab for children and young adults with type 1 diabetes (T1D).